Results 61 to 70 of about 238 (77)
Some of the next articles are maybe not open access.
Journal of Clinical Oncology, 2012
8513 Background: Ipilimumab (ipi), an antibody against cytotoxic T-lymphocyte-associated antigen-4, improves survival in patients (pts) with metastatic melanoma (MM); however, objective tumor responses are limited. NIBIT-M1 aims to investigate the efficacy and safety of ipi plus fotemustine (FTM), a cytotoxic alkylating drug, in pts with MM. Methods:
Di Giacomo AM +16 more
openaire +2 more sources
8513 Background: Ipilimumab (ipi), an antibody against cytotoxic T-lymphocyte-associated antigen-4, improves survival in patients (pts) with metastatic melanoma (MM); however, objective tumor responses are limited. NIBIT-M1 aims to investigate the efficacy and safety of ipi plus fotemustine (FTM), a cytotoxic alkylating drug, in pts with MM. Methods:
Di Giacomo AM +16 more
openaire +2 more sources
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT)
2010Introduction: As for a consolidated tradition, the VII annual meeting of the NIBIT (acronym for the Network Italiano per la Bioterapia dei Tumori, Italian Network for Tumor Biotherapy) took place in the Certosa of Pontignano, a Tuscan Carthusian monastery near Siena, on 1–3 October 2009.
Maio M +12 more
openaire +1 more source
Nature Genetics
Pleural mesothelioma (PM) has a poor prognosis and standard therapy with immune checkpoint inhibitors (ICIs) CTLA-4 and PD-1 is still clinically unsatisfying. No predictive biomarkers of ICI efficacy in PM are available yet. In the retrospective multicenter NIBIT-EPI-MESO study, multi-omics analysis of pre-ICI therapy tumor lesions from 91 patients ...
Luana Calabrò +30 more
openaire +5 more sources
Pleural mesothelioma (PM) has a poor prognosis and standard therapy with immune checkpoint inhibitors (ICIs) CTLA-4 and PD-1 is still clinically unsatisfying. No predictive biomarkers of ICI efficacy in PM are available yet. In the retrospective multicenter NIBIT-EPI-MESO study, multi-omics analysis of pre-ICI therapy tumor lesions from 91 patients ...
Luana Calabrò +30 more
openaire +5 more sources
Cancer Immunology Research
Abstract Background: Pleural mesothelioma (PM) is an aggressive malignancy with a poor prognosis. The clinical efficacy of standard therapy with immune checkpoint inhibitors (ICI) is limited and heterogeneous across PM subtypes.
Giovanna Sabella +2 more
exaly +2 more sources
Abstract Background: Pleural mesothelioma (PM) is an aggressive malignancy with a poor prognosis. The clinical efficacy of standard therapy with immune checkpoint inhibitors (ICI) is limited and heterogeneous across PM subtypes.
Giovanna Sabella +2 more
exaly +2 more sources
Cancer Research
Abstract Background: In the NIBIT Foundation-sponsored phase Ib NIBIT-M4 study, we firstly reported that the hypomethylating agent (HMA) guadecitabine (G), a prodrug of decitabine (D), followed by ipilimumab (I), was safe and had promising clinical and tumor-immunomodulatory activity in ...
Danna Chan +2 more
exaly +2 more sources
Abstract Background: In the NIBIT Foundation-sponsored phase Ib NIBIT-M4 study, we firstly reported that the hypomethylating agent (HMA) guadecitabine (G), a prodrug of decitabine (D), followed by ipilimumab (I), was safe and had promising clinical and tumor-immunomodulatory activity in ...
Danna Chan +2 more
exaly +2 more sources
Journal of Clinical Oncology
8052 Background: Pleural mesothelioma (PM) is an aggressive malignancy with a poor prognosis. The clinicalefficacy of standard therapy with immune checkpoint inhibitors (ICI) is limited and heterogeneous acrossPM subtypes. Tumor-intrinsic characteristics (
Luana Calabrò +19 more
openaire +1 more source
8052 Background: Pleural mesothelioma (PM) is an aggressive malignancy with a poor prognosis. The clinicalefficacy of standard therapy with immune checkpoint inhibitors (ICI) is limited and heterogeneous acrossPM subtypes. Tumor-intrinsic characteristics (
Luana Calabrò +19 more
openaire +1 more source
Sixth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, 16–18 October 2008
Cancer Immunology, Immunotherapy, 2009Maio M +33 more
openaire +5 more sources
Cancer Immunity and Immunotherapy Beyond COVID-19
Cancer Immunology, Immunotherapy, 2023Vincenzo Bronte, Silvia Dusi
exaly

